Peptide Drugs Reverse Mitochondrial Damage in Friedreich Ataxia — But Reveal a Therapeutic Catch
The peptides TAT-P110 and SS-31 both reversed mitochondrial fragmentation in Friedreich ataxia cells through Drp1-dependent mechanisms, but TAT-P110 decreased ATP levels while SS-31 did not — revealing that fragmentation may be a beneficial compensatory response.
Quick Facts
What This Study Found
TAT-P110 and SS-31 both reversed Drp1-dependent mitochondrial fragmentation in FRDA cells. TAT-P110 decreased ATP levels (suggesting fragmentation is homeostatic). SS-31 reversed fragmentation without affecting ATP. Both act through the same pathway with different downstream effects.
Key Numbers
TAT-P110 reversed fragmentation + decreased ATP; SS-31 reversed fragmentation without ATP drop; Drp1-dependent; combination = SS-31 alone
How They Did This
In vitro study. Frataxin-knockdown fibroblasts and FRDA patient fibroblasts. Drp1 inhibition by TAT-P110 peptide. Cardiolipin stabilization by SS-31 peptide. Mitochondrial morphology, Drp1 activity, and ATP levels measured. Drug combination testing.
Why This Research Matters
This study reveals a critical nuance for mitochondrial disease therapy: not all mitochondrial "damage" should be reversed. Some morphological changes are the cell's way of coping. Therapies must distinguish beneficial compensation from harmful dysfunction.
The Bigger Picture
This has implications beyond Friedreich ataxia. Many neurodegenerative diseases show mitochondrial fragmentation, and drugs to reverse it are being developed. This study warns that blindly reversing fragmentation could impair compensatory energy production.
What This Study Doesn't Tell Us
In vitro fibroblast study — neuronal and cardiac cells (most affected in FRDA) may respond differently. ATP measurement is one bioenergetic parameter. Long-term effects and functional outcomes not assessed.
Questions This Raises
- ?Would SS-31 improve symptoms in Friedreich ataxia patients where TAT-P110 might not?
- ?Does the homeostatic fragmentation principle apply to other neurodegenerative diseases like Parkinson's?
- ?Can mitochondrial fragmentation be selectively reversed in disease-relevant tissues?
Trust & Context
- Key Stat:
- Helpful damage? Mitochondrial fragmentation in Friedreich ataxia may actually be helping cells maintain energy — reversing it with TAT-P110 decreased ATP, while SS-31 avoided this problem
- Evidence Grade:
- Moderate evidence: patient-derived fibroblast data with mechanistic analysis, but in vitro only.
- Study Age:
- Published 2021. SS-31 (elamipretide) is in clinical development for mitochondrial diseases.
- Original Title:
- Drp1-dependent peptide reverse mitochondrial fragmentation, a homeostatic response in Friedreich ataxia.
- Published In:
- Pharmacology research & perspectives, 9(3), e00755 (2021)
- Database ID:
- RPEP-05474
Evidence Hierarchy
Frequently Asked Questions
What is Friedreich ataxia?
Friedreich ataxia is a genetic disease caused by loss of frataxin, a mitochondrial protein. It causes progressive nerve damage, heart problems, and coordination loss. There is currently no approved treatment, though peptide drugs like SS-31 are being investigated.
Could SS-31 help Friedreich ataxia patients?
SS-31 (elamipretide) reversed mitochondrial damage in FRDA cells without depleting energy — a better profile than TAT-P110. SS-31 is in clinical development for mitochondrial diseases, and this study supports its potential for FRDA. Clinical trials would be needed to confirm benefit.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05474APA
Johnson, Joseph; Mercado-Ayón, Elizabeth; Clark, Elisia; Lynch, David; Lin, Hong. (2021). Drp1-dependent peptide reverse mitochondrial fragmentation, a homeostatic response in Friedreich ataxia.. Pharmacology research & perspectives, 9(3), e00755. https://doi.org/10.1002/prp2.755
MLA
Johnson, Joseph, et al. "Drp1-dependent peptide reverse mitochondrial fragmentation, a homeostatic response in Friedreich ataxia.." Pharmacology research & perspectives, 2021. https://doi.org/10.1002/prp2.755
RethinkPeptides
RethinkPeptides Research Database. "Drp1-dependent peptide reverse mitochondrial fragmentation, ..." RPEP-05474. Retrieved from https://rethinkpeptides.com/research/johnson-2021-drp1dependent-peptide-reverse-mitochondrial
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.